Capsules are laid out for inspection on the production line of a drug factory. (Photographer: Tomohiro Ohsumi/Bloomberg)
When the U.S. drug regulator effectively barred exports from Divi’s Laboratories Ltd.’s biggest facility in Visakhapatnam in March 2017, the maker of pharma raw materials wiped off half of its value in five months.The U.S. Food and Drug Administration cited improper controls, falsified or poor documentation and R&D that was inconsistent with good manufacturing practices for the import alert for Visakhapatnam Unit 2 that contributes 7...